Marc Wilson - Sep 26, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
CFO
Signature
Marc Wilson
Stock symbol
CRNX
Transactions as of
Sep 26, 2024
Transactions value $
-$895,500
Form type
4
Date filed
9/30/2024, 05:01 PM
Previous filing
Jul 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $382K +25K +22.5% $15.29 136K Sep 26, 2024 Direct
transaction CRNX Common Stock Sale -$1.28M -25K -18.37% $51.11 111K Sep 26, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -25K -21.93% $0.00 89K Sep 26, 2024 Common Stock 25K $15.29 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $51.11 per share. The range of sales prices on the transaction date was $50.28 to $51.54 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.